The U.S. P2Y12 inhibitors market comprises platelet aggregation inhibitors used to treat acute coronary syndrome including unstable angina, myocardial infarction, and coronary stent placements. P2Y12 inhibitors work by blocking a specific receptor called P2Y12, which helps prevent excessive platelet activation and aggregation. Increasing use of P2Y12 inhibitors in dual antiplatelet therapy along with aspirin for treating heart attacks and strokes has driven their demand. The U.S. P2Y12 inhibitors market is estimated to be valued at US$ 267.73 Mn in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Global P2Y12 Inhibitors Market Share are Abcam plc, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., BD Biosciences, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., BioLegend, Inc., Merck KGaA, Novus Biologicals, LLC, R&D Systems, Inc. (a Bio-Techne brand), Santa Cruz Biotechnology, Inc., Beckman Coulter, Inc., Miltenyi Biotec GmbH, GeneTex, Inc., MBL International Corporation. The market players are focused on expanding their product portfolios by launching new products to leverage growth opportunities.
The key opportunities in the U.S. P2Y12 inhibitors market include rising research activities for developing biomarkers and companion diagnostics for cardiac disorders. Identification of novel drug targets and prognostic biomarkers can assist in assessing drug response and tailoring antiplatelet therapy regimens. Furthermore, growing collaborations between industry players and research institutes will support market expansion.
Globally, the U.S. P2Y12 inhibitors market is expected to grow owing to increasing incidence of cardiovascular diseases across developing nations. As per the World Health Organization, cardiovascular diseases are the leading cause of death globally, with over 17 million deaths annually. Expansion of healthcare infrastructure and improving reimbursement scenarios in developing countries will boost the demand for P2Y12 inhibitors.
Market drivers
A key driver for the U.S. P2Y12 inhibitors market is the rising prevalence of cardiovascular diseases such as coronary artery disease, heart attack, and stroke in the country. As per the Centers for Disease Control and Prevention, in the U.S around 659,000 people die from heart disease each year—that’s 1 in every 4 deaths. Growing geriatric population, sedentary lifestyles, and increasing consumption of fast food have significantly increased the risk of cardiac disorders. This will consequently drive the need for P2Y12 inhibitors in the U.S. for better cardiovascular health management and treatment of related complications.
PEST ANALYSIS
Political: The U.S. healthcare system is highly regulated by various government policies and acts. Changes in healthcare laws and reimbursement policies may impact the growth of this market.
Economic: As the US economy grows steadily, it will positively impact healthcare spending and boost the demand for high-quality P2Y12 inhibitors used for treating various cardiovascular diseases.
Social: Rising geriatric population and growing prevalence of chronic illnesses like cancer, cardiac diseases are expected to fuel the social demand for effective drugs like P2Y12 inhibitors in the country.
Technological: Advancements in drug delivery mechanisms and development of novel P2Y12 inhibitors with improved efficiency are anticipated to open new growth opportunities over the forecast period. Companies are investing heavily in R&D to develop next-gen therapies.
In terms of value, the U.S. P2Y12 inhibitors market is concentrated in Southern and Western regions owing to high healthcare expenditures and large patient pool suffering from cardiac ailments in states like California, Texas and Florida.
The Midwestern region, which includes states such as Illinois, Ohio and Michigan, is expected to witness the fastest growth during the forecast period. This can be attributed to increasing public awareness about cardiovascular disorders, rising healthcare spending capacity and availability of advanced medical facilities in these states.
For more details on the report, Read- https://www.marketwebjournal.com/u-s-p2y12-inhibitors-market-growth-market-size-share-analysis/
